Get started
Author

Christiane A. Houde

Overexpression of the NOTCH ligand JAG2 in malignant plasma cells from multiple myeloma patients and cell lines
2004 · Christiane Houde, Yulin Li, et al. · Blood · 177
PDF
Magnetic Enhancement of Cell Retention, Engraftment, and Functional Benefit after Intracoronary Delivery of Cardiac-Derived Stem Cells in a Rat Model of Ischemia/Reperfusion
2012 · Ke Cheng, Konstantinos Malliaras, et al. · Cell Transplantation · 96
Intramyocardial Injection of Platelet Gel Promotes Endogenous Repair and Augments Cardiac Function in Rats With Myocardial Infarction
2012 · Ke Cheng, Konstantinos Malliaras, et al. · Journal of the American College of Cardiology · 92
PDF
Selinexor in Combination with R-CHOP for Frontline Treatment of Non-Hodgkin Lymphoma: Results of a Phase I Study
2021 · Erlene K. Seymour, Husain Yar Khan, et al. · Clinical Cancer Research · 25
Alteration of SMRT Tumor Suppressor Function in Transformed Non-Hodgkin Lymphomas
2005 · Lynda Song, Andrei Zlobin, et al. · Cancer Research · 19
PDF
Treatment Outcomes and Prognostic Factors with Lenalidomide, Bortezomib, and Dexamethasone (RVd) Alone Versus Rvd Plus Autologous Stem Cell Transplantation (ASCT) in African American (AA) Patients (Pts) with Newly Diagnosed Multiple Myeloma (NDMM) in the Determination Phase 3 Trial
2023 · Christiane A. Houde, Abdullah Khan, et al. · Blood · 5
SMRT; Not So Smart in Multiple Myeloma.
2007 · Pushpankur Ghoshal, Christiane Houde, et al. · Blood · 4
A Phase II Multicenter Single Arm Study of Ibrutinib in Patients with Relapsed or Refractory Classical Hodgkin Lymphoma
2017 · Radhakrishnan Ramchandren, Tycel Phillips, et al. · Blood · 2
A Phase I Trial of Pomalidomide, Bortezomib (Velcade), and Dexamethasone (PVD) As Initial Treatment of AL Amyloidosis and Light Chain Deposition Disease
2014 · Jeffrey Zonder, Christiane Houde, et al. · Blood · 2
Health-Related Quality of Life (HRQoL) Among Patients with Triple-Class Exposed Relapsed/Refractory Multiple Myeloma (RRMM) Treated with Linvoseltamab in Linker-MM1: Interim Assessment up to 36 Weeks of Treatment
2023 · James E. Hoffman, Naresh Bumma, et al. · Blood · 1
PDF
The Impact of Melphalan Conditioning Schedule on Post-Transplant Outcomes in AL Amyloidosis: A Multicenter Study with 1718 Patients
2023 · Eli Muchtar, Vaishali Sanchorawala, et al. · Blood · 1
PDF
A Phase II Study Evaluating Safety and Efficacy of Polatuzumab Vedotin in Combination with Rituximab, Cyclophosphamide, Doxorubicin, and Prednisone in Patients with Previously Untreated Double and Triple Hit Lymphoma
2021 · Dipenkumar Modi, Seongho Kim, et al. · Blood · 1
The presence of the FRA12E/SMRT fragile site in the genome of prostate cancer patients is a predictor of metastatic development
2006 · Lionel Coignet, Christiane Houde, et al. · Clinical Cancer Research · 1
Inadequate Racial Reporting among References Forming the Basis of NCCN Guidelines for Multiple Myeloma and Systemic Light Chain Amyloidosis
2025 · Christiane Houde, Nikhil Vojjala, et al. · Clinical Lymphoma Myeloma & Leukemia
An Investigator Initiated Study of RCHOP in Combination with Selinexor (KPT-330) in Diffuse Large B Cell Lymphoma and Richter Transformation
2024 · Dipenkumar Modi, Jay Yang, et al. · Blood
PDF
Insufficient Representation and Reporting of Race in the References Forming the Basis of the National Comprehensive Cancer Network Guidelines for Multiple Myeloma
2024 · Danielle Ross, Stephen Caucci, et al. · Blood
PDF
Trial in Progress: Iberdomide and Daratumumab As Maintenance Therapy after an Autologous Stem Cell Transplant for Multiple Myeloma (the IBEX Trial)
2024 · Andrew Kin, Jeffrey A. Zonder, et al. · Blood
PDF
Underrepresentation and Underreporting of Race/Ethnicity in Systemic Light Chain Amyloidosis NCCN Guidelines
2024 · Katrina Reid, Nikhil Vojjala, et al. · Blood
PDF
A Decentralized Phase II Open-Label Trial Assessing the Safety and Efficacy of Dapagliflozin in Renal AL Amyloidosis (FLORAL)
2024 · Aditi Sharma, Joel Topf, et al. · Blood
PDF
Supplementary Data from Selinexor in Combination with R-CHOP for Frontline Treatment of Non-Hodgkin Lymphoma: Results of a Phase I Study
2023 · Erlene K. Seymour, Husain Yar Khan, et al.
PDF
Data from Selinexor in Combination with R-CHOP for Frontline Treatment of Non-Hodgkin Lymphoma: Results of a Phase I Study
2023 · Erlene K. Seymour, Husain Yar Khan, et al.
Data from Selinexor in Combination with R-CHOP for Frontline Treatment of Non-Hodgkin Lymphoma: Results of a Phase I Study
2023 · Erlene K. Seymour, Husain Yar Khan, et al.
Supplementary Data from Selinexor in Combination with R-CHOP for Frontline Treatment of Non-Hodgkin Lymphoma: Results of a Phase I Study
2023 · Erlene K. Seymour, Husain Yar Khan, et al.
from Multiple Myeloma Patients and Cell Lines
2016 · Christiane Houde, Yulin Li, et al.
Chemotherapy can induce breakage in the FRA12E/SMRT fragile site.
2007 · Christiane Houde, Jean Dolce, et al. · Cancer Research
Works count: 27
Citation count: 426
H-index: 5
I10-index: 5
Year
Topic
Type